Mohamed Abou El Hassan1, Alexandra Stoianov2, Petra A T Araújo2, Tara Sadeghieh2, Man Khun Chan2, Yunqi Chen2, Edward Randell3, Michelle Nieuwesteeg2, Khosrow Adeli4. 1. CALIPER Program, Department of Pediatric Laboratory Medicine, The Hospital of Sick Children, Toronto, ON, Canada; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada. 2. CALIPER Program, Department of Pediatric Laboratory Medicine, The Hospital of Sick Children, Toronto, ON, Canada. 3. Eastern Health, St. John's, NL, Canada. 4. CALIPER Program, Department of Pediatric Laboratory Medicine, The Hospital of Sick Children, Toronto, ON, Canada; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada. Electronic address: khosrow.adeli@sickkids.ca.
Abstract
OBJECTIVE: The CALIPER program has established a comprehensive database of pediatric reference intervals using largely the Abbott ARCHITECT biochemical assays. To expand clinical application of CALIPER reference standards, the present study is aimed at transferring CALIPER reference intervals from the Abbott ARCHITECT to Beckman Coulter AU assays. DESIGN AND METHODS: Transference of CALIPER reference intervals was performed based on the CLSI guidelines C28-A3 and EP9-A2. The new reference intervals were directly verified using up to 100 reference samples from the healthy CALIPER cohort. RESULTS: We found a strong correlation between Abbott ARCHITECT and Beckman Coulter AU biochemical assays, allowing the transference of the vast majority (94%; 30 out of 32 assays) of CALIPER reference intervals previously established using Abbott assays. Transferred reference intervals were, in general, similar to previously published CALIPER reference intervals, with some exceptions. Most of the transferred reference intervals were sex-specific and were verified using healthy reference samples from the CALIPER biobank based on CLSI criteria. It is important to note that the comparisons performed between the Abbott and Beckman Coulter assays make no assumptions as to assay accuracy or which system is more correct/accurate. CONCLUSION: The majority of CALIPER reference intervals were transferrable to Beckman Coulter AU assays, allowing the establishment of a new database of pediatric reference intervals. This further expands the utility of the CALIPER database to clinical laboratories using the AU assays; however, each laboratory should validate these intervals for their analytical platform and local population as recommended by the CLSI.
OBJECTIVE: The CALIPER program has established a comprehensive database of pediatric reference intervals using largely the Abbott ARCHITECT biochemical assays. To expand clinical application of CALIPER reference standards, the present study is aimed at transferring CALIPER reference intervals from the Abbott ARCHITECT to Beckman Coulter AU assays. DESIGN AND METHODS: Transference of CALIPER reference intervals was performed based on the CLSI guidelines C28-A3 and EP9-A2. The new reference intervals were directly verified using up to 100 reference samples from the healthy CALIPER cohort. RESULTS: We found a strong correlation between Abbott ARCHITECT and Beckman Coulter AU biochemical assays, allowing the transference of the vast majority (94%; 30 out of 32 assays) of CALIPER reference intervals previously established using Abbott assays. Transferred reference intervals were, in general, similar to previously published CALIPER reference intervals, with some exceptions. Most of the transferred reference intervals were sex-specific and were verified using healthy reference samples from the CALIPER biobank based on CLSI criteria. It is important to note that the comparisons performed between the Abbott and Beckman Coulter assays make no assumptions as to assay accuracy or which system is more correct/accurate. CONCLUSION: The majority of CALIPER reference intervals were transferrable to Beckman Coulter AU assays, allowing the establishment of a new database of pediatric reference intervals. This further expands the utility of the CALIPER database to clinical laboratories using the AU assays; however, each laboratory should validate these intervals for their analytical platform and local population as recommended by the CLSI.
Authors: Ji Yeon Sung; Jong Do Seo; Dae-Hyun Ko; Min-Jeong Park; Sang Mee Hwang; Sohee Oh; Sail Chun; Moon-Woo Seong; Junghan Song; Sang Hoon Song; Sung Sup Park Journal: Ann Lab Med Date: 2021-03-01 Impact factor: 3.464
Authors: Ruohua Yan; Kun Li; Yaqi Lv; Yaguang Peng; Nicholas Van Halm-Lutterodt; Wenqi Song; Xiaoxia Peng; Xin Ni Journal: BMC Med Res Methodol Date: 2022-04-10 Impact factor: 4.615
Authors: Houman Tahmasebi; Victoria Higgins; Angela W S Fung; Dorothy Truong; Nicole M A White-Al Habeeb; Khosrow Adeli Journal: EJIFCC Date: 2017-03-08